Stamaril
Stamaril Uses, Dosage, Side Effects, Food Interaction and all others data.
Live, attenuated virus stimulates active immunity to Yellow fever; conveys active immunity via stimulation of production of endogenously produced antibodies. Yellow fever vaccine is used for active immunisation against yellow fever. Each dose (usually 0.5 ml) contains at least 1000 mouse LD50 units.
Trade Name | Stamaril |
Generic | Yellow Fever Vaccine |
Yellow Fever Vaccine Other Names | Flavivirus yellow fever virus 17D-204 whole, Yellow fever virus 17D/tiantan live antigen, Yellow fever virus live antigen, A, Yellow fever virus strain 17D (live, attenuated), Yellow fever virus strain 17D-204 live (attenuated) antigen, Yellow fever virus strain 17D-204 live antigen, Yellow fever, live attenuated |
Weight | 1000mouseldu50, 1000iu/0.5ml, |
Type | Injection, Im/deep Sc Injection, Injectable Powder For Injection, Subcutaneous Powder For Injection |
Groups | Approved, Investigational |
Therapeutic Class | Vaccines, Anti-sera & Immunoglobulin |
Manufacturer | Sanofi Aventis (pakistan) Ltd,, Sanofi Pasteur |
Available Country | Pakistan, Bangladesh, Australia, United States, Portugal |
Last Updated: | September 19, 2023 at 7:00 am |
![Stamaril Stamaril](https://www.medicinesfaq.com/media/png/stamaril.png)
Uses
Prophylaxis of Yellow fever infection
Stamaril is also used to associated treatment for these conditions: Yellow Fever
How Stamaril works
Stamaril is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection . Vaccination with Yellow Fever vaccine is considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Stamaril, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days .
Dosage
Stamaril dosage
Primary Vaccination:
- Adults and Children >9 months: 0.5 mL of reconstituted vaccine administered as a single dose.
- Children : The vaccine must not be given to children
The vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed.
Elderly
: The dose is the same as for adults. However, due to a higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection.
Re-Vaccination
: Re-vaccination with 1 dose of 0.5 mL is recommended every 10 years in persons considered to be at risk of exposure. International Health Regulations (IHR) require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.For IM use, the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults.
Side Effects
Fever, headache, seizure, myalgia, weakness, focal neurological defects. Local inj site reactions e.g. erythema, pain, oedema.
Precaution
Caution when used in immunocompromised patients e.g. patients receiving chemo-radiation therapy or other immunosuppressive therapy such as high-dose corticosteroids and patients 65 yr. Monitor for adverse events 10-30 days post-vaccination.
Interaction
Immunosuppressants eg. cytotoxic agents, systemic steroids.
Pregnancy & Breastfeeding use
Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Lactation: There is a theoretical risk of transmission of vaccine components to the infants from breast-feeding mothers, lactation constitutes a contraindication, particularly when infants are <9 months of age because of the risk of encephalitis
Contraindication
- Hypersensitivity reaction to eggs, chicken proteins or to any component of this vaccine.
- Serious hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any yellow fever vaccine.
- Immunosuppression, whether congenital, idiopathic or as a result of treatment with systemic steroids (greater than the standard dose of topical or inhaled steroids), radiotherapy or cytotoxic drugs.
- History of thymus dysfunction (including thymoma, thymectomy).
- Symptomatic HIV infection.
- Asymptomatic HIV infection when accompanied by evidence of impaired immune function (see Precautions).
- Age
- Current severe febrile illness.
Innovators Monograph
You find simplified version here Stamaril
Stamaril contains Yellow Fever Vaccine see full prescribing information from innovator Stamaril Monograph, Stamaril MSDS, Stamaril FDA label